

K130034

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
(21 CFR 807.92)
for *UNI-PICC™*

MAR 08 2013

SUBMITTER:

Health Line International Corporation
803 N. 1250 W. – STE 1
Centerville, Utah 84014

ESTABLISHMENT REGISTRATION NUMBER:

3006097687

CONTACT:

Nola L. Benstog
QA/RA Director
Telephone: 801-773-7798
Fax: 801-820-8007
Email: nbenstog@hlic.net

DATE PREPARED:

January 3, 2013

NAME OF MEDICAL DEVICE:

Proprietary Name:	<i>UNI-PICC™</i>
Regulation Name:	Percutaneous, Implanted, Long-term Intravascular Catheter
Common/Usual Name:	Peripherally Inserted Central Catheter (PICC), single, double and triple lumen

DEVICE CLASSIFICATION:

Classification Panel:	General Hospital
Regulatory Class:	Class II
Product Code:	LJS
Regulation Number:	21 CFR 880.5970

PREDICATE DEVICES:

Proprietary Name:	<i>SYNERGY™ CT PICC (K101329)</i>
Regulation Name:	Percutaneous, Implanted, Long-term Intravascular Catheter
Common/Usual Name:	Peripherally Inserted Central Catheter (PICC), single, double and triple lumen
Classification Panel:	General Hospital
Regulatory Class:	Class II
Product Code:	LJS
Regulation Number:	21 CFR 880.5970

Proprietary Name: **2.6F Vascu-PICC® (K102966)**
Regulation Name: Percutaneous, Implanted, Long-term Intravascular Catheter
Common/Usual Name: Peripherally Inserted Central Catheter (PICC)
Classification Panel: General Hospital
Regulatory Class: Class II
Product Code: LJS
Regulation Number: 21 CFR 880.5970

Proprietary Name: **Vascu-PICC® and Midline Catheters, Single, Double and Triple Lumen (K091586)**
Regulation Name: Percutaneous, Implanted, Long-term Intravascular Catheter
Common/Usual Name: Catheter, Intravascular, Therapeutic, Long-Term
Classification Panel: General Hospital
Regulatory Class: Class II
Product Code: LJS
Regulation Number: 21 CFR 880.5970

DEVICE DESCRIPTION:

The UNI-PICC™ is a family of peripherally inserted central venous catheters designed to perform infusion, intravenous therapy and blood sampling. The catheters, made of radiopaque polyurethane tubing, are inserted peripherally. Each UNI-PICC™ has a kink resistant catheter design. The UNI-PICC™ kit includes a catheter and introduction components. The catheter is supplied sterile and non-pyrogenic in a variety of kit configurations.

The UNI-PICC™ is indicated for dwell times shorter or greater than 30 days. The UNI-PICC™ product line has catheters in 3Fr, 4 Fr and 5 Fr single lumen, 4 Fr, 5 Fr and 6 Fr dual lumen and 5 Fr and 6 Fr triple lumen. All catheters range from approximately 30 - 60 cm long. The catheters are attached to an injection-molded polyurethane hub that has extension legs with Luer lock fittings for access attachment.

INTENDED USE:

The *UNI-PICC™* is intended to be used by medical professionals for short-term or long-term peripheral access to the central venous system for infusion, intravenous therapy and for blood sampling.

The intended use for the *UNI-PICC™* has not changed from that of the *SYNERGY™ CT PICC (K101329)* predicate device, with the exception of the removal of power injection.

INDICATIONS FOR USE:

The *UNI-PICC™* Peripherally Inserted Central Catheter is indicated for short or long term access to the central venous system for intravenous administration of fluids, medications and/or nutritional therapy when prescribed. Blood sampling may also be conducted with *UNI-PICC™*.

The 3F *UNI-PICC™* Peripherally inserted Central Catheter is indicated for short or long term access to the central venous system via peripheral insertion in neonates, infants and children. It may be used for administration of fluids, medications and/or nutritional therapy when prescribed.

TECHNOLOGICAL COMPARISON TO PREDICATE DEVICES:

New device is compared to Marketed Device? Yes. It is compared to three legally marketed predicate devices.

Does the new device have the same indication statements? Yes, the first paragraph of the indications for use statement is the same as the *SYNERGY™ CT PICC (K101329)* with the exception of the removal of power injection. The last paragraph of the indications for use statement is the same as the *2.6F Vascu-PICC® (K102966)* predicate with the exception of noting the 3F size.

Do the differences alter the intended therapeutic/diagnostic/etc. effect (i.e. deciding may consider impact on safety and effectiveness)? No, the differences do not alter the intended effect of the device.

Does the new device have the same technological characteristics, e.g. design, material, etc.? Yes. The PICC device of this submission, the *UNI-PICC™*, is identical to that of the predicate device (K101329). In fact, the *UNI-PICC™* and the *SYNERGY™ CT PICC* are manufactured by the same company, Health Line International Corporation, the submitter of this submission. The basic fundamental scientific technology of the device has not

changed. There may be minor variations in the contents of the introduction kit components.

Could the new characteristics affect safety or effectiveness? No.

Do the new characteristics raise new types of safety and effectiveness questions? No.
There are no new types of safety and effectiveness questions.

Do accepted scientific methods exist for assessing effects of the new characteristics? Yes.

The FDA's *Guidance on Premarket Notification [510(k)] Submission for Short-Term and Long-Term Intravascular Catheters*, dated 3/16/95 was used to determine the appropriate methods for evaluating the device's performance.

Sterilization requirements of ISO 11135:2007, *Sterilization of Health Care Products - Requirements for Validation and Routine Control -- Ethylene Oxide Sterilization*.

Biocompatibility requirements according to of ISO-10993, *Biological Evaluation of Medical Devices Part 1: Evaluation and Testing*. Test profiles for externally communicating, blood-contacting, long-term devices will be met.

These and other standards were used to determine the appropriate methods for evaluating the device's performance.

Are performance data available to assess effects of new characteristics? Yes. Verification testing was performed according to protocols based on the above-referenced guidance document recommendations and additional standards.

Do performance data demonstrate equivalence? Yes. Performance data gathered in design verification testing demonstrated that the *UNI-PICC™* is substantially equivalent to the noted predicate devices.

CONCLUSION

The *UNI-PICC™* met all established acceptance criteria for performance testing and design verification testing. This testing demonstrated that the *UNI-PICC™* is safe and effective for its intended use, and based on FDA's decision tree is substantially equivalent to the *SYNERGY™ CT PICC* (K101329), *2.6F Vascul-PICC®* (K102966) and *Vascul-PICC® and Midline Catheters, Single, Double and Triple Lumen* (K091586).



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

March 8, 2013

Ms. Nola Benstog
Quality Assurance and Regulatory Affairs Director
Health Line International Corporation
803 North 1250 West, Suite 1
CENTERVILLE UT 84014

Re: K130034
Trade/Device Name: UNI-PICC™
Regulation Number: 21 CFR 880.5970
Regulation Name: Percutaneous, Implanted, Long-Term Intravascular Catheter
Regulatory Class: II
Product Code: LJS
Dated: January 3, 2013
Received: January 8, 2013

Dear Ms. Benstog:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Anthony D. Watson". The signature is stylized with a large "A" and "W".

Anthony D. Watson, B.S., M.S., M.B.A.
Director
Division of Anesthesiology, General Hospital,
Respiratory, Infection Control and
Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications For Use

510(k) Number (if known): K130034

Device Name: **UNI-PICC™**

Indications For Use:

The UNI-PICC™ Peripherally Inserted Central Catheter is indicated for short or long term access to the central venous system for intravenous administration of fluids, medications and/or nutritional therapy when prescribed. Blood sampling may also be conducted with UNI-PICC™.

The 3F UNI-PICC™ Peripherally inserted Central Catheter is indicated for short or long term access to the central venous system via peripheral insertion in neonates, infants and children. It may be used for administration of fluids, medications and/or nutritional therapy when prescribed.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Sajjad H. Syed

Digitally signed by Sajjad H. Syed
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People, cn=Sajjad H. Syed,
0.9.2342.19200300.100.1.1=2000601742
Date: 2013.03.05 14:32:26 -05'00'

(Division Sign-Off)
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K130034